Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares traded up 5.9% on Friday . The stock traded as high as $7.32 and last traded at $7.19. 3,029,561 shares traded hands during mid-day trading, an increase of 126% from the average session volume of 1,339,620 shares. The stock had previously closed at $6.79.

Several research analysts recently weighed in on the company. BidaskClub raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Cowen and Company reaffirmed a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, June 17th. Maxim Group reaffirmed a “buy” rating and issued a $9.00 target price on shares of Keryx Biopharmaceuticals in a research report on Thursday, July 20th. Zacks Investment Research lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, ValuEngine raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. Keryx Biopharmaceuticals presently has an average rating of “Hold” and an average target price of $7.48.

The company’s market capitalization is $853.81 million. The stock’s 50 day moving average is $7.00 and its 200 day moving average is $6.49.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.60). Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The business had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.51 million. During the same period in the previous year, the firm posted ($0.42) EPS. The firm’s revenue for the quarter was up 62.4% on a year-over-year basis. Analysts anticipate that Keryx Biopharmaceuticals, Inc. will post ($1.23) earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. lifted its stake in shares of Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 38,316 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 102 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Keryx Biopharmaceuticals by 1.2% in the 1st quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 300 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 335 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 590 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC lifted its stake in shares of Keryx Biopharmaceuticals by 1.6% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 65,000 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 1,000 shares during the last quarter. 65.19% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Keryx Biopharmaceuticals, Inc. (KERX) Trading 5.9% Higher” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/17/keryx-biopharmaceuticals-inc-kerx-trading-5-9-higher.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.